371917-17-8

Basic information

• Product Name: 1-(Trifluoromethyl)cyclopropanemethanol
• Synonyms: 1-(Trifluoromethyl)cyclopropanemethanol;(1-TrifluoroMethyl-cyclopropyl)-Methanol
• CAS NO: 371917-17-8
• Molecular Formula: C₅H₇F₃O
• Molecular Weight: 140
• Mol File: 371917-17-8.mol

Chemical Properties

• Boiling Point: 95℃
• Flash Point: 51℃
• Appearance: /
• Density: 1.356
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 15.10±0.10(Predicted)
• CAS DataBase Reference: 1-(Trifluoromethyl)cyclopropanemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Trifluoromethyl)cyclopropanemethanol(371917-17-8)
• EPA Substance Registry System: 1-(Trifluoromethyl)cyclopropanemethanol(371917-17-8)

Safety Data

• Hazardous Substances Data: 371917-17-8(Hazardous Substances Data)

Usage

Uses

[1-(trifluoromethyl)cyclopropyl]methanol is a useful research chemical.

Upstream product

• 208242-25-5 methayl 1-(trifluoromethyl)cyclopropanecarboxylate 
• 277756-46-4 1-(trifluoromethyl)cyclopropanecarboxylic acid 
• 277756-43-1 1-trifluoromethyl-cyclopropanecarbonyl fluoride 

Downstream Products

• 1360569-11-4 (3R,4R,5S,6R)-2-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-10-3 (3R,4S,5S,6R)-2-(4-fluoro-3-(4-((1-( trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1360569-09-0 4-bromo-1-fluoro-2-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)benzene 
• 1360569-02-3 (3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-01-2 (3R,4S,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 1360569-00-1 4-bromo-1-chloro-2-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)benzene 
• 1360569-46-5 (2S,3R,4R,5S,6R)-2-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-45-4 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-fluoro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-40-9 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1360569-39-6 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1360569-32-9 (2R,3S,4R,5R,6S)-2-(hydroxymethyl)-6-(4-methyl-3-(4-((1-(trifluoromethyl)cyclopropyl)methoxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1229311-61-8 1-(trifluoromethyl)cyclopropane-1-carbaldehyde 

Relevant articles and documents

SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY

The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa

5-(PYRIDIN-3-YL)OXAZOLE ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR

Provided are 5-(pyridin-3-yl) oxazole compounds, the compositions comprising these compounds and the uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR

Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.